On Jan. 29, as China was still battling the remnants of a wave of COVID-19 infections that emerged after the government dismantled its zero-COVID policy, the national drug regulator said it had given conditional approval to two homegrown antivirals specifically designed for treating the virus.
Caixin
Uncertainties hurt prospects of China's homegrown COVID antivirals
SIM0417 and VV116 lack data on effectiveness, face competition from Paxlovid
A patient's information is registered at the entrance to the fever clinic of the Central Hospital of Wuhan amid a coronavirus outbreak on Dec. 31.
Read Next
.jpg?width=700&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=394)
Latest on Caixin
